Dr. Anup Kumar Singh is currently a postdoctoral fellow in the laboratory of Anjana Rao at the La Jolla Institute for Immunology in San Diego, California. His research mainly focuses on understanding the molecular basis for alterations in chromatin landscapes and its pathogenic consequences like malignancy.
Dr. Singh obtained his undergraduate degree in Bioengineering from Bundelkhand University, Jhansi, India. He earned his master’s in Biotechnology from Indian Institute of Technology (IIT) Guwahati, India where he was awarded postgraduate scholarship from MHRD, Government of India. To pursue his graduate studies, Dr. Singh was awarded a national research fellowship from Council of Scientific and Industrial Research (CSIR), India. He studied the role of the histone methyltransferase EZH2 in cancer stem cells (CSCs) and therapy resistance in the laboratory of Dr. Dipak Datta at Central Drug Research Institute, India and was awarded his PhD from Jawaharlal Nehru University, New Delhi, India. In his graduate research work he found that EZH2 play a key role in suppressing the expression of proapoptotic death receptors 4 and 5 (DR4 and DR5) in CSCs population that makes them resistant to TRAIL therapy. In recognition of this work, Dr. Singh was awarded the National Cancer Research Institute (NCRI), UK prize award in 2015.
Dr. Singh’s current research interest focusses on exploring the role of the tumor suppressor BRCA1 in regulating heterochromatin architecture. In this research endeavor, he expects to unravel driver events for initiation of cancers in general and define currently unknown risk factor proteins whose mutations might be associated with increased susceptibility to ovarian cancer.